19:36 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture studies identified a pteridinylbenzamide-based dual PLK1/BRD4 inhibitor that could help treat AML. Chemical synthesis and screening of analogs of a pteridinylbenzamide-based tool compound PLK1 inhibitor in enzyme activity...
21:11 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Trovagene prices $4.5M follow-on

On Dec. 15, cancer company Trovagene Inc. (NASDAQ:TROV) raised $4.5 million through the sale of 15 million units at $0.30 in a follow-on underwritten by H.C. Wainwright. Each unit comprises a share and a five-year...
01:00 , Jul 21, 2017 |  BC Week In Review  |  Financial News

Trovagene raises $7.1M in direct public offering

Cancer company Trovagene Inc. (NASDAQ:TROV) raised $7.1 million through the sale of 6.2 million shares at $1.15 in a registered direct offering on July 14. In a concurrent private placement, the investors also received 4.6...
21:38 , Jul 11, 2017 |  BC Extra  |  Preclinical News

Researchers link PLK1 inhibition to CV risks

In a paper published in Nature Medicine , researchers at the Spanish National Cancer Research Centre (CNIO) identified an unexpected cardiovascular risk in mice with polo-like kinase 1 ( PLK1 ) inhibition, including mice treated...
19:13 , Mar 24, 2017 |  BC Week In Review  |  Company News

Nerviano, Trovagene deal

Nerviano granted Trovagene exclusive, worldwide rights to develop and commercialize PCM-075 (NMS-1286937). The candidate is the first cancer therapeutic in Trovagene's pipeline. Nerviano will receive $2 million up front and is eligible for development milestones...
07:00 , Oct 17, 2016 |  BioCentury  |  Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Trovagene sales and marketing update

Trovagene said Blue Cross Blue Shield (BCBS) of Illinois will cover Trovagene’s Trovera liquid biopsy tests. The biotech markets Trovera EGFR , a non-invasive molecular diagnostic to detect EGFR exon 19 deletions and exon 20...
07:00 , May 2, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/29 cls Dynavax Technologies Corp. (NASDAQ:DVAX) RBC Capital Markets Simos Simeonidis Downgrade Sector performer (from outperform) -26% $16.41 Simeonidis also...
01:12 , Apr 28, 2016 |  BC Extra  |  Company News

Management tracks

Cancer company ImmunoGen Inc. (NASDAQ:IMGN) hired Mark Enyedy as president, CEO and a director, effective May 16. Enyedy was EVP and head of corporate development at Shire plc (LSE:SHP; NASDAQ:SHPG). He replaces Daniel Junius, who...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Company News

Trovagene, Stratose LLC sales and marketing update

Trovagene said Stratose gave preferred provider status to Trovagene and will cover the company’s Precision Cancer Monitoring tests. Stratose covers more than 8.6 million lives. Trovagene markets the cell-free PCR tests to detect BRAF ,...